Health-related Quality of Life Measurements in Patients with Actinic Keratosis: A Systematic Review
DOI:
https://doi.org/10.2340/actadv.v106.44163Keywords:
health related quality of life, quality of life, patient reported outcomes, actinic keratosis, systematic reviewAbstract
Actinic keratosis is a common, chronic, and potentially pre-cancerous skin disease that can negatively impact patients’ health-related quality of life. This systematic review aimed to identify and describe the questionnaires used to assess health-related quality of life in patients with actinic keratosis and summarize reported impacts. Four databases (EMBASE, PsycINFO, PubMed, and Cochrane Library) were searched up to February 2025. Two reviewers independently screened articles, and risk of bias was assessed using tools appropriate to study design. Of 639 records, 37 studies including 9,326 patients met inclusion criteria. Most studies were interventional (59%) and of moderate to high quality (64%). Health-related quality of life was assessed using 3 disease-specific, 3 dermatology-specific, and 2 generic questionnaires. The most frequently used instruments were the Actinic Keratosis Quality of Life (n = 13) and the Dermatology Life Quality Index (n = 16). All questionnaires detected health-related quality of life impairment, especially during treatment. Actinic Keratosis Quality of Life identified patient subgroups with greater health-related quality of life reduction, including females, younger individuals, patients with comorbidities, and those with a history of skin cancer. All health-related quality of life questionnaires captured impairment in patients with actinic keratosis. The Actinic Keratosis Quality of Life and Dermatology Life Quality Index questionnaires were widely used. Actinic Keratosis Quality of Life identified subpopulations with health-related quality of life impairment. Among studies reporting mean health-related quality of life scores, the Dermatology Life Quality Index ranged from 1.55 to 24 and the Actinic Keratosis Quality of Life from 4.22 to 17, reflecting very broad variability and underlying differences in actinic keratosis severity across study populations.
Downloads
References
Malvehy J, Stratigos AJ, Bagot M, Stockfleth E, Ezzedine K, Delarue A. Actinic keratosis: current challenges and unanswered questions. J Eur Acad Dermatol Venereol 2024; 38(Suppl. 5): 3–11. DOI: https://doi.org/10.1111/jdv.19559
de Oliveira ECV, da Motta VRV, Pantoja PC, Ilha CS de O, Magalhães RF, Galadari H, Leonardi GR. Actinic keratosis – review for clinical practice. Int J Dermatol 2019; 58(4): 400–407. DOI: https://doi.org/10.1111/ijd.14147
Esmann S. Patients’ perspectives on actinic keratosis. Curr Probl Dermatol (Switzerland) 2015; 46: 8–13. DOI: https://doi.org/10.1159/000366530
Esmann S, Jemec GBE. Management of actinic keratosis patients: a qualitative study. J Dermatol Treat2007; 18(1): 53–58. DOI: https://doi.org/10.1080/09546630601028737
Finlay AY, Salek MS, Abeni D, Tomás-Aragonés L, van Cranenburgh OD, Evers AWM, et al. Why quality of life measurement is important in dermatology clinical practice. J Eur Acad Dermatol Venereol 2017; 31: 424–431. DOI: https://doi.org/10.1111/jdv.13985
Chernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. J Eur Acad Dermatol Venereol 2019; 33: 816–827. DOI: https://doi.org/10.1111/jdv.15487
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372. DOI: https://doi.org/10.1136/bmj.n71
Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary. Mil Med Res. Military Medical Research 2020; 7: 1–11. Available from: https://mmrjournal.biomedcentral.com/track/pdf/10.1186/s40779-020-00238-8.pdf DOI: https://doi.org/10.1186/s40779-020-00238-8
Olsen EA, Lisa Abernethy M, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol; 1991; 24: 738–743. DOI: https://doi.org/10.1016/0190-9622(91)70113-G
Esmann S, Vinding GR, Christensen KB, Jemec GBE. Assessing the influence of actinic keratosis on patients’ quality of life: the AKQoL questionnaire. Br J Dermatol 2013; 168(2): 277–283. DOI: https://doi.org/10.1111/bjd.12036
Longo I, Serra-Guillén C. Quality of life, behaviour and attitudes towards actinic keratosis in Spain: the PIQA study. Actas Dermosifiliogr 2018; 109: 331–339. DOI: https://doi.org/10.1016/j.adengl.2018.01.003
Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, Hædersdal M. Health related quality of life in patients with actinic keratosis: an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes 2015; 13: 1–9. DOI: https://doi.org/10.1186/s12955-015-0295-4
Neri L, Peris K, Longo C, Calvieri S, Frascione P, Parodi A, Actinic Keratosis – TReatment Adherence INitiative (AK-TRAIN) study group. Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy or the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol 2019; 33: 93–107. DOI: https://doi.org/10.1111/jdv.15142
Norrlid H, Norlin JM, Holmstrup H, Malmberg I, Sartorius K, Thormann H, et al. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. J Dermatolog Treat 2018; 29: 68–73. DOI: https://doi.org/10.1080/09546634.2017.1329514
Vis K, Waalboer-Spuij R, Snels DGCTM, Hollestein LM. Validity and reliability of the Dutch adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). Dermatology 2018; 234: 60–65. DOI: https://doi.org/10.1159/000489118
Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399–405. DOI: https://doi.org/10.1097/MLG.0b013e31802e2d88
Hasan ZU, Ahmed I, Matin RN, Homer V, Lear JT, Ismail F, et al. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). Br J Dermatolo 2022; 18: 324–337. DOI: https://doi.org/10.1111/bjd.20974
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Hongbo Y, Thomas CL, Harrison MA, Sam Salek M, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol 2005; 125: 659–664. DOI: https://doi.org/10.1111/j.0022-202X.2005.23621.x
Tejada C dos S, Mendoza-Sassi RA, Almeida Jr HL de, Figueiredo PN, Tejada VF dos S. Impact on the quality of life of dermatological patients in southern Brazil. An Bras Dermatol 2011; 86: 1113–1121. DOI: https://doi.org/10.1590/S0365-05962011000600008
Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105–110. DOI: https://doi.org/10.1007/BF02737863
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433–1440. DOI: https://doi.org/10.1001/archderm.1997.03890470111018
Nijsten TEC, Sampogna F, Chren MM, Abeni DD. Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 1244–1250. DOI: https://doi.org/10.1038/sj.jid.5700212
Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012; 30: 231–236. DOI: https://doi.org/10.1016/j.det.2011.11.003
Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009; 218(2): 151–154. DOI: https://doi.org/10.1159/000182253
Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 2013; 8: 35–41. DOI: https://doi.org/10.2147/PPA.S47126
Waalboer-Spuij R, Holterhues C, Van Hattem S, Schuttelaar MLA, Gaastra MTW, Kuijpers DIM, et al. Patient perception of imiquimod treatment for actinic keratosis and superficial basal cell carcinoma in 202 patients. Dermatology 2015; 231: 56–62. DOI: https://doi.org/10.1159/000381420
EuroQol Research Foundation. EQ-5D-5L User Guide 2019 (Version 3.0). Available from: EuroQol Research Foundation. EQ-5D-5L User Guide 2019 (Version 3.0).
Philipp-Dormston WG, Müller K, Novak B, Strömer K, Termeer C, Hammann U, NMSC-QoL Study Group. Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. J Eur Acad Dermatol Venereol 2018; 32: 1138–1146. DOI: https://doi.org/10.1111/jdv.14703
RAND Health Care 20-Item Short Form Survey (SF-20) [Internet] [accessed 2025-01-29]. Available from: https://www.rand.org/health-care/surveys_tools/mos/20-item-short-form.html
Thomas SI, Taylor MA, Plampton K, Sharma D, Samson KK, Wysong A, et al. Assessing quality of life in field cancerization: an institutional cohort analysis. Dermatol Surg 2024; 50: 1202–1203. DOI: https://doi.org/10.1097/DSS.0000000000004311
Anthony E, Lun K, Smith SD. Full face ingenol mebutate for actinic keratosis: patient perspective. Int J Dermatol 2019; 58: e6–e9. DOI: https://doi.org/10.1111/ijd.14263
Hanke WC, Norlin JM, Mark Knudsen K, Larsson T, Stone S. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatol Treat 2016; 27: 450–455. DOI: https://doi.org/10.3109/09546634.2016.1160024
Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology 2013; 226: 253–259. DOI: https://doi.org/10.1159/000349992
Răducu L, Avino A, Purtan RP, Balcangiu-Stroescu AE, Balăn DG, Timofte D, et al. Quality of life in patients with surgically removed skin tumors. Medicina (Lithuania) 2020; 56: 3–9. DOI: https://doi.org/10.3390/medicina56020066
Prinsen CAC, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MKA, EADV Taskforce on Quality of Life. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013; 27: 1195–203. DOI: https://doi.org/10.1111/jdv.12090
Grada A, Feldman SR, Bragazzi NL, Damiani G. Patient-reported outcomes of topical therapies in actinic keratosis: a systematic review. Dermatol Ther 2021; 34: 1–10. DOI: https://doi.org/10.1111/dth.14833
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Zohra F. Ahmadzay, Mattias A.S. Henning, Gregor B.E. Jemec, Gabrielle R. Vinding
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
